Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: BRAF
Name: B-Raf proto-oncogene serinethreonine kinase
Location: 07q34
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT01904968 Impact of Methylation Alterations in Colon Cancer Epidemiology and Prognosis View
NCT04044430 Encorafenib Binimetinib and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer View
NCT01738451 A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors View
NCT01897116 A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma View
NCT00975897 Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer View
NCT01240590 A Phase III Trial of Crolibulin EPC2407 Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer ATC View
NCT01306045 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer Small Cell Lung Cancer and Thymic Malignancies View
NCT01688232 The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer View
NCT03363217 Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPKERK Pathway View
NCT02902042 Encorafenib Binimetinib Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma View
NCT01442935 Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases View
NCT01543113 cKIT BRAFNRAS Mutations in Advanced Melanoma Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project View
NCT01611675 LeflunomideVemurafenib in V600 Mutant Met Melanoma View
NCT01700699 Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors View
NCT01774526 Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype View
NCT04221438 Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement View
NCT01876212 Dendritic Cell Vaccines Dasatinib for Metastatic Melanoma View
NCT01878396 Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors View
NCT04249843 Study of Safety Pharmacokinetics and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors View
NCT02038348 Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors a Pilot Study View
NCT02130466 A Study of the Safety and Efficacy of Pembrolizumab MK-3475 in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma MK-3475-022KEYNOTE-022 View
NCT02138292 A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma View
NCT03399487 A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement View
NCT02281760 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease View
NCT01006980 A Study of Vemurafenib RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma BRIM 3 View
NCT02310451 Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma Role of Exosomes View
NCT02331914 GIST Assessment of Tumor Mutations and TKI Plasma Exposure View
NCT04253080 Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma Value in Prognosis andor in Predictive Response to Immune Checkpoint Inhibitors View
NCT01276379 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy Cetuximab View
NCT02663232 Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma View
NCT02729298 First-in-human Study of Oral TP-0903 a Novel Inhibitor of AXL Kinase in Patients With Advanced Solid Tumors View
NCT04262635 Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer View
NCT02904031 Study of I Line FOLFOX Panitumumab vs 5FU Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients View
NCT06414304 Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy View
NCT02968303 Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy View
NCT03089268 Molecular and Histological Characteristics of Serrated Lesions of the Colon View
NCT03113604 Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins MDR in Resistance to Treatment With Sorafenib in CHC Patients View
NCT03115164 Astrocytoma Desmoplastic Gamliogliomes DIA DIG - Study of the French Cohort of the Last 20 Years Clinical Anatomopathological Molecular and Radiological Charactersics View
NCT03167268 Panitumumab Skin Toxicity Prevention Trial View
NCT03231722 First Line mFOLFOXIRI PANITUMUMAB vs mFOLFOX PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS View
NCT03501615 An Early Access Programme for Moxetumomab Pasudotox in RelapsedRefractory Hairy Cell Leukemia View
NCT03721120 Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer View
NCT03784378 Continued Access to RXDX-105 View
NCT04240717 Shared Decision Making on Immunotherapy in Oncology View
NCT03803397 Arm 1 Lysate Pulsed Dendritic Cells PV-001-DC in Patients With Melanoma View
NCT03874026 Study of FolfiriCetuximab in FcGammaRIIIa VV Stage IV Colorectal Cancer Patients View
NCT03949153 Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis View
NCT03972046 Neoadjuvant Use of Talimogene Laherparepvec and BRAFMEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma View
NCT03979651 MEK and Autophagy Inhibition in MetastaticLocally Advanced Unresectable Neuroblastoma RAS NRAS Melanoma View
NCT04065776 Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma View
NCT04133948 Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 11-measurable Stage III Cutaneous or Unknown Primary Melanoma View
NCT04154163 Appropriate Dosing to Optimise Personalised Cancer Treatments View
NCT04170556 Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma GOING View
NCT04551521 CRAFT The NCT-PMO-1602 Phase II Trial View
NCT05370807 A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma View
NCT04673955 BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment View
NCT04735900 lead-in FOLICOLOR Trial Following Therapy Response Through Liquid Biopsy in Metastatic Colorectal Cancer Patients View
NCT02857270 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With AdvancedMetastatic Cancer View
NCT02828202 Follow-up of a National Cohort of Melanoma Resectable Stage II Stage III or IV Patients or Unresectable Primary View
NCT04787341 PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence View
NCT04911998 A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients View
NCT04949113 Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma View
NCT04965220 HLX208 BRAF V600E Inhibitor in Combination With Trametinib in Patients With Advanced Solid Tumors View
NCT04984369 The Efficacy of HLX208 BRAF V600E Inhibitor With Cetuximab for Metastatic Colorectal Cancer mCRC With BRAF V600E Mutation After First-line Treatment View
NCT05127759 The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer mCRC With BRAF V600E Mutation View
NCT05180825 Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy View
NCT05412706 Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy View
NCT01949194 Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers View
NCT05541380 A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients TOPICS-THYROID View
NCT05760586 Expanded Access Program EAP for Tovorafenib DAY101 in RAF-Altered Relapsed or Refractory Low-Grade Glioma View
NCT06054191 Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations View
NCT05892653 A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors View
NCT05984615 Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients View
NCT06048315 A Single Center Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody View
NCT06106802 Lazertinib Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment View
NCT02893085 Pancreatico-biliary Tumor Mutation Profiling in Bile Samples View
NCT06196424 A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer FAHIC - Lung View
NCT02906059 Study of Irinotecan and AZD1775 a Selective Wee 1 Inhibitor in RAS or BRAF Mutated Second-line Metastatic Colorectal Cancer View
NCT02786602 LRP1 Methylation and Colon Cancer View
NCT01100840 A Retrospective Study of Biomarkers in Non-Small Cell Lung Cancer View
NCT03975231 Dabrafenib Trametinib and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer View
NCT03989297 PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma View
NCT04319354 Evaluation of cfDNA as a Marker of Response in Rectal Cancer View
NCT03585686 A Combination of Vemurafenib Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation View
NCT01943422 Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma View
NCT04158544 Immune Monitoring in Metastatic Melanoma View
NCT01673737 A Phase IIb Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer View
NCT01704703 Study of FOLFIRI Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS PIK3Ca BRAF and NRAS Genes Detected With Highly Sensitive Techniques View
NCT01682083 Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma COMBI-AD View
NCT01198743 Presence of Circulating Tumor DNA in Colorectal Cancer View
NCT01713972 Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors View
NCT01256359 Docetaxel With or Without AZD6244 in Melanoma View
NCT01266967 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain View
NCT01264380 A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma View
NCT02810262 Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer POUMOS View
NCT02751177 Detection of KRAS NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer View
NCT01298570 RegorafenibFOLFIRI Versus PlaceboFOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer View
NCT00491140 Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab View
NCT01308840 Gemcitabine Oxaliplatin and Panitumumab in KrasB-raf Wild-Type Biliary Track and Gallbladder Cancer View
NCT01307397 A Study of Vemurafenib in Participants With Metastatic Melanoma View
NCT01340833 Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors View
NCT00422448 Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi View
NCT01362296 An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer View
NCT01363232 Safety Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients View
NCT01748149 Vemurafenib in Children With RecurrentRefractory BRAF Gene V600E BRAFV600E-Mutant Gliomas View
NCT00405587 Safety Study of PLX4032 in Patients With Solid Tumors View
NCT01750918 BRAFMEKEGFR Inhibitor Combination Study in Colorectal Cancer CRC View
NCT04439279 Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes MATCH-Subprotocol R View
NCT01449058 A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors View
NCT01910181 A Study of Vemurafenib Zelboraf in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma View
NCT02910700 Nivolumab With Trametinib and Dabrafenib or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma View
NCT04462471 Vemurafenib Plus Copanlisib in Radioiodine-Refractory RAIR Thyroid Cancers View
NCT02670707 VinblastinePrednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis LCH View
NCT01495988 Trial of VemurafenibCobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma View
NCT00551486 Pyrosequencing of the BRAFV600E Mutation View
NCT01531361 Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations View
NCT01534897 Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 View
NCT04515979 Vactosertib in Combination With Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer NSCLC Subjects View
NCT01562899 A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors View
NCT04526782 ENCOrafenib with Binimetinib in BRAF NSCLC View
NCT01960023 Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer View
NCT04525326 Conversion Therapy of RASBRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases View
NCT01841463 Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation View
NCT01588860 Mutation Analysis and Copy Number Changes of KRAS and BRAF Gene in Taiwanese Cases of Biliary Tact Adenocarcinoma View
NCT03108209 Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment View
NCT01586195 Study Of Zelboraf Vemurafenib in Patients With Locally-Advanced Unresectable Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E View
NCT04544202 Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection View
NCT01972347 Neoadjuvant Dabrafenib Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma View
NCT01596140 Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer View
NCT04554680 Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF MEK Blockade for Re-differentiation Therapy View
NCT04566393 Expanded Access to Ulixertinib BVD-523 in Patients with Advanced MAPK Pathway-Altered Malignancies View
NCT01636622 Study of Vemurafenib Carboplatin and Paclitaxel View
NCT00866177 MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma View
NCT02306850 Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma View
NCT00888134 Selumetinib in Cancers With BRAF Mutations View
NCT04607421 A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer View
NCT02052193 Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIaIIb Study View
NCT00948467 Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies View
NCT00955578 Genetic Identification ID of Segmental Dysplastic Nevi View
NCT01667419 A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma View
NCT02314143 Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib View
NCT02314481 Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity View
NCT04655157 Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma View
NCT01677741 A Study to Determine Safety Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects View
NCT02231775 Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation View
NCT01689519 A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma View
NCT01038037 First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer View
NCT01037127 Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor View
NCT04666272 Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection View
NCT01693419 S-1 Gemcitabine and Erlotinib for Advanced Pancreatic Cancer View
NCT01700582 French National Observatory of the Patients With Non-small Cell Lung NSCLC and Molecular Testings View
NCT02251314 Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma View
NCT02691780 Study to Evaluate the Safety and Efficacy of Sorafenib in Subject With Refractory Solid Tumors View
NCT01108107 Neoadjuvant Treatment of Colon Cancer View
NCT01143753 A Study of RO5212054 PLX3603 in Participants With BRAF V600-Mutated Advanced Solid Tumors View
NCT04722575 Combination or Sequence of Vemurafenib Cobimetinib and Atezolizumab in High-risk Resectable Melanoma View
NCT01153763 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma View
NCT01582997 A Phase I Study to Investigate the Safety Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors View
NCT01512251 BKM120 Combined With Vemurafenib PLX4032 in BRAFV600EK Mutant Advanced Melanoma View
NCT04739566 Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer View
NCT01726738 LCCC 1128 Open Label Phase II Trial of the BRAF Inhibitor Dabrafenib and the MEK Inhibitor Trametinib in Unresectable Stage III and Stage IV BRAF Mutant Melanoma Correlation of Resistance With the Kinome and Functional Mutations View
NCT01739764 An Extension Rollover Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol View
NCT03416933 Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma View
NCT04759846 Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma View
NCT01227889 A Study Comparing GSK2118436 to Dacarbazine DTIC in Previously Untreated Subjects With BRAF Mutation Positive Advanced Stage III or Metastatic Stage IV Melanoma View
NCT01225536 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF andor NRAS Mutations View
NCT03428126 Study of Durvalumab MEDI4736 Anti-PD-L1 and Trametinib MEKi in MSS Metastatic Colon Cancer View
NCT01231568 An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor View
NCT01245062 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600EK Mutation-positive Melanoma View
NCT01744860 Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples View
NCT01740648 Trametinib Fluorouracil and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer View
NCT01262963 An Absorption Distribution Metabolism and Excretion ADME Study of Single Oral Dose 14C GSK2118436 in Subjects With BRAF Mutant Solid Tumors View
NCT05611229 Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden View
NCT02296112 Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations View
NCT01758575 Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities View
NCT01280643 Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer View
NCT01286753 A Study of Vemurafenib RO5185426 in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation View
NCT02410863 Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma View
NCT01754376 Combined BRAF-Targeted Therapy Immunotherapy for Melanoma View
NCT02357732 Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib andor Trametinib View
NCT01765569 A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma View
NCT01765543 A Pharmacokinetics PK Study to Investigate the Effect of Rifampin on PK of Vemurafenib Zelboraf View
NCT01767454 Study of Dabrafenib - Trametinib in Combination With Ipilimumab for V600EK Mutation Positive Metastatic or Unresectable Melanoma View
NCT01358812 FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer View
NCT02447939 Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma View
NCT02450149 Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib in Subjects With BRAF Mutation Refractory Solid Tumors View
NCT02380443 AlloStim Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer View
NCT01777776 Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma View
NCT04831528 Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center Phase II Clinical Study View
NCT01781026 Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases View
NCT01417442 BRAF V600E Mutations In Papillary Thyroid Carcinoma View
NCT01437618 First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer View
NCT01794793 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies View
NCT01791309 Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer View
NCT01477463 Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers View
NCT02484833 Erbitux MEtastatic Colorectal Cancer Strategy Study View
NCT04904419 Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection View
NCT04913285 A Study to Evaluate KIN-2787 in Participants With BRAF andor NRAS Mutation Positive Solid Tumors View
NCT03101254 LY3022855 With BRAFMEK Inhibition in Patients With Melanoma View
NCT04943198 Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis View
NCT01584648 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma View
NCT01597908 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600EK Cutaneous Melanoma View
NCT01605162 Phase 2 Study of the PolyADP-Ribose Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma View
NCT01603212 Systemic Therapy With Interferon Interleukin-2 and BRAF Inhibitor View
NCT01619774 An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor View
NCT01616199 Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma View
NCT03051035 First-in-Human Study of KO-947 in Non-Hematological Malignancies View
NCT02961283 Study of ASN003 in Subjects With Advanced Solid Tumors View
NCT01640444 Influence of BRAF and PIK3K Status on the Efficacy of 5-FluorouracilLeucovorinOxaliplatin FOLFIRI Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and 3 Circulating Tumor Cells CTC View
NCT01656642 A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma View
NCT01657591 Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage IIIIV Melanoma View
NCT05003622 Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors View
NCT05019534 Tolerability and Safety of Vemurafenib Cetuximab Combined With Camrelizumab for BRAF V600E-mutated MSS Metastatic Colorectal Cancer View
NCT02969681 Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer View
NCT01673854 Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma View
NCT02974725 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma View
NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies View
NCT01683188 HD IL-2 Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma View
NCT01709292 Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer View
NCT05051592 Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RASRAF Wild-type Metastatic Colorectal Cancer Patients View
NCT01711632 BRAF Inhibitor Vemurafenib in Patients With Relapsed or Refractory Hairy Cell Leukemia View
NCT01718808 Cetuximab for Elderly Patients With mCRC View
NCT01719380 Study of LGX818 and Cetuximab or LGX818 BYL719 and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer View
NCT01721603 Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets View
NCT01723202 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer View
NCT03000374 Induction Therapy With Panitumumab mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery View
NCT01765556 A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma View
NCT01767623 A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants View
NCT01787500 Vemurafenib Cetuximab and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery View
NCT01804140 A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf Vemurafenib View
NCT03139513 A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib Cotellic During the French Early Access Program Temporary Authorization for Use TAU View
NCT03311542 Expanded Access for Pembrolizumab MK-3475 View
NCT01826448 A Phase 1b Open Label Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma View
NCT01835184 Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery View
NCT01867697 Nordic 8 - A Phase II Trial View
NCT01877811 Study of RXDX-105 Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors View
NCT01876641 Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib View
NCT01898585 An Open-Label Study of Zelboraf Vemurafenib in Patients With Braf V600 Mutation Positive Metastatic Melanoma View
NCT01894672 BRAF Inhibitor LGX818 Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation View
NCT05195632 Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer View
NCT01902173 Uprosertib Dabrafenib and Trametinib in Treating Patients With Stage IIIC-IV Cancer View
NCT01909453 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma View
NCT01928940 Japan PhIII of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600EK Mutation Positive Advanced Solid Tumors Phase I Part or Cutaneous Melanoma Phase II Part View
NCT03340506 Dabrafenib andor Trametinib Rollover Study View
NCT05223673 Phase 3 Study of FutuximabModotuximab in Combination With TrifluridineTipiracil Versus TrifluridineTipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer View
NCT01954043 A Pharmacokinetics PK Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors View
NCT01983124 Vemurafenib Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib View
NCT01990248 An Observational Safety Study in Zelboraf Vemurafenib-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma ZeSS View
NCT03201458 Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer View
NCT05275374 XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation View
NCT02012231 Phase IIIa Study to Evaluate the Safety PK PD and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers View
NCT05299580 Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients a Prospective Phase II Open Label Multicentre Study - Bioliquid TAILOR Study - BIOTAILOR View
NCT02027961 Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone View
NCT02039947 Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain View
NCT05308446 Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation View
NCT03220035 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With BRAF V600 Mutations A Pediatric MATCH Treatment Trial View
NCT03224208 Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients View
NCT02068079 A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma View
NCT02082665 Effects of Dabrafenib on the Single Dose Pharmacokinetics PK of Rosuvastatin and Midazolam View
NCT02089724 Long-term Outcome After Vemurafenib BRAF Inhibitors Interruption in Erdheim-chester Disease View
NCT03235245 Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib View
NCT02094872 Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic View
NCT05356897 Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients 3T Study View
NCT02115035 A Single Agent Study to Evaluate the Overall Response Rate Safety and Tolerability of Orally Administered Vemurafenib View
NCT02145143 Enhancing Radioiodine RAI Incorporation Into BRAF Mutant RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib A Pilot Study View
NCT02143999 An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma View
NCT05388877 E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma View
NCT02145910 Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases View
NCT02143050 Study of Dabrafenib Trametinib and Metformin for Melanoma Patients View
NCT02159066 LGX818 and MEK162 in Combination With a Third Agent BKM120 LEE011 BGJ398 or INC280 in Advanced BRAF Melanoma View
NCT02164916 S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer View
NCT04021420 Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma View
NCT03989115 Dose-EscExp RMC4630 Cobi in RelapsedRefractory Solid Tumors RMC4630 Osi in EGFR Locally AdvMeta NSCLC View
NCT05441514 Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia View
NCT02257424 Dabrafenib Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma View
NCT02263898 Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations View
NCT02296203 Cetuximab Rechallenge in Irinotecan-pretreated mCRC KRAS NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy CRICKET View
NCT03430947 Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases View
NCT02304809 Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations View
NCT02308553 Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma View
NCT05810740 Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations View
NCT03493230 Detection of Plasmatic Cell-free BRAF and NRAS Mutations a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy MALT View
NCT03798977 Preclinical Validation of New Anti-melanoma Compounds View
NCT02367859 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma View
NCT05540951 VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer View
NCT02381808 Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China View
NCT01813214 The Effects of Vemurafenib Cobimetinib on Immunity in Patients With Melanoma View
NCT02416232 Access Study of Trametinib for Subjects With Advanced Unresectable Stage IIIc or Distant Metastatic Stage IV BRAF V600EK Mutation Positive Cutaneous Melanoma View
NCT02427893 Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma View
NCT02456701 Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 View
NCT02452294 Buparlisib in Melanoma Patients Suffering From Brain Metastases BUMPER View
NCT05600894 Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic SyndromeMyeloproliferative Neoplasm View
NCT03551626 Study of DabrafenibTrametinib in the Adjuvant Treatment of Stage III BRAF V600 Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes View
NCT03553329 Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK View
NCT02508077 FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer View
NCT02535078 Phase 1b2 Study of the Combination of IMCgp100 With Durvalumab andor Tremelimumab in Advanced Cutaneous Melanoma View
NCT02537600 Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis View
NCT02608034 A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics PK of Vemurafenib at Steady State View
NCT02619058 A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients View
NCT05691504 Testing the Combination of APG-1252 Pelcitoclax and Cobimetinib in Recurrent Ovarian and Endometrial Cancers View
NCT05699590 Galectin-3 in Papillary Thyroid Carcinoma View
NCT02626065 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies View
NCT05706779 Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer View
NCT02631447 Sequential Combo Immuno and Target Therapy SECOMBIT Study View
NCT02645149 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma View
NCT04061980 Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer View
NCT05727904 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma View
NCT05722886 DETERMINE Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial - Master Screening Protocol View
NCT02684058 Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors View
NCT05743036 ZN-c3 in Adult Participants With Metastatic Colorectal Cancer View
NCT02721459 XL888 Vemurafenib Cobimetinib for Unresectable BRAF Mutated Stage IIIIV Melanoma View
NCT05768178 DETERMINE Trial Treatment Arm 05 Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers View
NCT03781219 A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation View
NCT01820364 LGX818 in Combination With Agents MEK162 BKM120 LEE011 BGJ398 INC280 in Advanced BRAF Melanoma View
NCT05806268 Patient Characteristics Associated Factors and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients View
NCT02836548 HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma View
NCT03989895 Intratumoral Injection of Dengue Virus-1 45AZ5 PV-001-DV in Patients With Melanoma View
NCT05868629 Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors View
NCT04581824 Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer NSCLC View
NCT02915666 A Clinical Trial of Patients With Melanoma View
NCT02928224 Study of Encorafenib Cetuximab Plus or Minus Binimetinib vs IrinotecanCetuximab or Infusional 5-Fluorouracil 5-FUFolinic Acid FAIrinotecan FOLFIRICetuximab With a Safety Lead-in of Encorafenib Binimetinib Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer View
NCT01231594 A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors View
NCT04310397 Dabrafenib Trametinib and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIBCD Melanoma View
NCT02942706 Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC View
NCT05487235 A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors View
NCT02967692 A Study of the Anti-PD1 Antibody PDR001 in Combination With Dabrafenib and Trametinib in Advanced Melanoma View
NCT04317599 A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer mCRC View
NCT04322383 Binimetinib for People With RelapsedRefractory BRAF Wild Type Hairy Cell Leukemia and Variant View
NCT04324112 Encorafenib Plus Binimetinib for People With BRAF V600 Mutated RelapsedRefractory HCL View
NCT05304546 Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma View
NCT03005639 ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma View
NCT05963087 Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer View
NCT01519427 Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib View
NCT03088176 Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma View
NCT03118817 Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF KRAS or NRAS Mutant Solid Cancers View
NCT04375527 Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma View
NCT03146962 High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies View
NCT03155217 Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old View
NCT04390243 Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation View
NCT04511013 A Study to Compare the Administration of Encorafenib Binimetinib Nivolumab Versus Ipilimumab Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases View
NCT03224767 Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma View
NCT03272464 INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors View
NCT03273153 A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma View
NCT06102902 Testing the Addition of Anti-cancer Drug ZEN003694 to the Usual Chemotherapy Treatment Cetuximab Plus Encorafenib for Colorectal Cancer View
NCT04775095 BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib a Retrospective Evaluation View
NCT03332589 E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases CNS View
NCT03333343 Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC View
NCT06148402 Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With UnresectableMetastatic Colorectal Cancer View
NCT04620330 A Study of Avutometinib VS-6766 Defactinib in Recurrent KRAS G12V Other KRAS and BRAF Non-Small Cell Lung Cancer View
NCT04790448 Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer View
NCT03391050 A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma View
NCT03405272 Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC View
NCT03415126 A Study of ASN007 in Patients With Advanced Solid Tumors View
NCT04800822 PF-07284892 in Participants With Advanced Solid Tumors View
NCT03898908 Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain View
NCT03455764 MCS110 With BRAFMEK Inhibition in Patients With Melanoma View
NCT03457896 Study of Neratinib Trastuzumab or Neratinib Cetuximab in Patients With KRASNRASBRAFPIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status View
NCT06207656 Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer View
NCT04652258 Pyrexia Management Using an IL-6 Antibody in BRAF Melanoma Patients Treated With Dabrafenib Trametinib - Immunotherapy View
NCT01840527 Utility of Novel BRAF Test for Melanoma View
NCT05312398 CAPRI 2 GOIM Study Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen View
NCT03663647 Advanced Melanoma in Russian Experience View
NCT04903119 Nilotinib Plus DabrafenibTrametinib in Metastatic Melanoma View
NCT03511963 A Clinical Study to Compare the Efficacy Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC View
NCT03543969 Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma View
NCT03563729 Melanoma Metastasized to the Brain and Steroids View
NCT03593993 A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas View
NCT03634982 Dose Escalation of RMC-4630 Monotherapy in RelapsedRefractory Solid Tumors View
NCT03668431 Dabrafenib Trametinib PDR001 In Colorectal Cancer View
NCT03693170 Encorafenib Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer View
NCT03714958 Trametinib HDM201 in CRC Patients With RASRAF Mutant and TP53 Wild-type AdvancedMetastatic Colorectal Cancer Mutant and TP53 Wild-type View
NCT06362694 Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy View
NCT04744831 Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer View
NCT03727763 Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer IMPROVEMENT View
NCT02700763 18FDabrafenib Molecular Imaging in Melanoma Brain Metastasis View
NCT04760080 Association of Hydroxychloroquine BRAF and MEK Inhibitors in Metastatic Melanoma a Retrospective Case-control Study View
NCT03794297 Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations View
NCT05080361 Rechallenge of BRAF - MEK Inhibitors Following an Adverse Event in Patients With Cancer View
NCT03839342 Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations View
NCT03843775 A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers View
NCT03878719 Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma View
NCT05103891 Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations View
NCT03919071 Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma View
NCT03925350 Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination HR Mutation View
NCT03944356 BRAF-MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients View
NCT06489067 Study of the Thyroid Function and Echostructural Morphology in Patients Affected With Rasopathies ECORAS2023 View
NCT03973918 Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG View
NCT05004350 A Study Evaluating the Combination of Encorafenib and Cetuximab Versus IrinotecanCetuximab or Infusional 5-fluorouracil 5-FUFolinic Acid FAIrinotecan FOLFIRICetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer View
NCT04007848 Cobimetinib for BRAF-wild-type or Mutated Histiocytoses View
NCT04035096 The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients View
NCT05022030 First-line mCapOXCetuximab vs mFOLFOX6Cetuximab for Metastatic Left-sided CRC With Wild-type RASBRAF Genes View
NCT04039672 Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFiMEKi in BRAF Mutated Melanoma View
NCT06603376 Irinotecan Hydrochloride Liposome Injection Ⅱ Combined with Fluorouracil Folinic Acid Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer View
NCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer View
NCT04074096 Binimetinib Encorafenib Pembrolizumab - Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis View
NCT04108481 Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer View
NCT06550453 Safety and Efficacy of Pembrolizumab in Combination With Bevacizumab CapeOX in the Neoadjuvant Treatment of RAS-mutated BRAF Wild-type Microsatellite-stabilized Locally Advanced Colorectal Cancer View
NCT05054725 Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies View
NCT05062096 Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence View
NCT06578559 Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC View
NCT05171374 pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE View
NCT04190628 Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors View
NCT02407509 Phase I Trial of VS-6766 Alone and in Combination With Everolimus View
NCT04225390 Preconditioning of Tumor Tumor Microenvironment and the Immune System to Immunotherapy View
NCT04238624 Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer View
NCT04248387 Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma View
NCT05710406 Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer View
NCT04294160 A Study of Select Drug Combinations in Adult Patients With AdvancedMetastatic BRAF V600 Colorectal Cancer View
NCT05900219 Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer a Phase II Clinical Study View
NCT04417621 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma View
NCT04418167 JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations View
NCT04425239 Intermittent or Continuous Panitumumab Plus FOLFIRI for RASB-RAF Wild-type Metastatic Colorectal Cancer View
NCT06011772 EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer View
NCT04439292 Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes MATCH-Subprotocol H View
NCT04452877 A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC View
NCT04479514 Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy View
NCT04489433 Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma View
NCT04488003 Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations View
NCT04507919 Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer View
NCT04527549 Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600EK Melanoma View
NCT04534283 A Basket Trial of an ERK12 Inhibitor LY3214996 in Combination With Abemaciclib View
NCT04543188 A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement View
NCT04557956 Testing the Addition of the Anti-cancer Drug Tazemetostat to the Usual Treatment Dabrafenib and Trametinib for Metastatic Melanoma That Has Progressed on the Usual Treatment View
NCT04585815 Study of Immunotherapy Sasanlimab in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer NSCLC Landscape 1011 Study View
NCT04624373 Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc View
NCT04633902 Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination HR Mutation View
NCT04657991 A Clinical Trial of Three Study Medicines Encorafenib Binimetinib and Pembrolizumab in Patients With Advanced or Metastatic Melanoma View
NCT04675710 Pembrolizumab Dabrafenib and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer View
NCT04706754 Pan-Canadian Lung Cancer Observational Study PALEOS View
NCT04718038 Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS NRAS and BRAF V600E Metastatic Colorectal Cancer View
NCT01524978 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers View
NCT04781270 mFOLFOXIRIBev vs mFOLFOX6Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases View
NCT02561533 Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma View
NCT06074588 Sacituzumab Tirumotecan MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC With EGFR Mutations or Other Genomic Alterations MK-2870-004 View
NCT06251934 Real-World Patient Characteristics Treatment Patterns and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma View
NCT04943224 Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients View
NCT05170360 Evaluation of Some Risk Factors Associated With Colorectal Cancer View
NCT04961619 Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma View
NCT04985604 Tovorafenib DAY101 Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors View
NCT05016869 Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS BRAF Wild-type Metastatic Colorectal Cancer View
NCT06275919 Regorafenib for Recurrent Grade 2 and 3 Meningioma MIRAGE Trial View
NCT05092802 The Efficacy of HLX208 BRAF V600E Inhibitor for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment View
NCT05065398 A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation View
NCT05074966 The Efficacy and Safety of Modified XELOXmXELOX Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts View
NCT05092815 The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis LCH and Erdheim-Chester Disease ECD With BRAF V600E Mutation View
NCT05102292 The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer ATC With BRAF V600 Mutation View
NCT05114603 A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation View
NCT06180005 Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano INOND View
NCT06194877 A Study to Investigate BGB-3245 Brimarafenib With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers View
NCT06194929 Defactinib and Avutometinib With or Without Encorafenib for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma View
NCT05263453 HL-085Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600EK Mutation View
NCT05260684 Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US View
NCT06381570 Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With RecurrentProgressive RAF Altered Low Grade Gliomas View
NCT06539702 Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology View
NCT06400225 Testing BVD-523FB Ulixertinib as Potentially Targeted Treatment in Cancers With Genetic Changes MATCH - Subprotocol Z1L View
NCT06475989 Study of Targeted Therapy vs Chemotherapy in Patients With Thyroid Cancer View
NCT06411600 Combination Therapy for BRAF-V600E Metastatic CRCm View
NCT06653517 Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma View
NCT06553781 A Single-arm Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma View
NCT06557291 Relapse-Free Survival With Adjuvant DabrafenibTrametinib Therapy in Patients With BRAF V600-mutated Stage IIIIV Melanoma View
NCT06440850 Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation View
NCT06610682 Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib View
NCT06449989 Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer View
NCT01922583 AUY922 in Patient With Stage IV NSCLC View
NCT05525273 Treatment of BRAF B-Rapidly Accelerated Fibrosarcoma Mutated Papillary Craniopharyngioma View
NCT05528406 A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation View
NCT01942993 The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma View
NCT01940809 Ipilimumab With or Without Dabrafenib Trametinib andor Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery View
NCT01941927 Trametinib With GSK2141795 in BRAF Wild-type Melanoma View
NCT05546905 A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer OCTOPUS View
NCT01947023 Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery View
NCT05576896 Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory View
NCT01978236 DabrafenibTrametinib BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op Phase IIB Melanoma With Brain MetsBiomarkers and Metabolites View
NCT01973322 Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy andor Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma a Randomized Proof-of-principle Phase II Study View
NCT05639413 A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer View
NCT01989585 Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma View
NCT05641493 A Phase IbII Clinical Trial to Evaluate the Safety and Efficacy of HLX208HLX10 in NSCLC With BRAF V600E Mutation View
NCT05668585 A Study to Characterize the Safety Tolerability and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors View
NCT03543306 Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation View
NCT06536400 Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation View
NCT00849407 Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma View
NCT05756556 T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma View
NCT02034110 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers View
NCT02036086 Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases View
NCT05848219 Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib Trametinib and Encorafenib Binimetinib View
NCT00936221 Comparison of AZD6244 in Combination With Dacarbazine Versus vs Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients View
NCT05876806 Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations View
NCT00959127 A Study of ARRY-438162 MEK162 in Patients With Advanced Cancer View
NCT05881746 Anatomical Resection VS Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness View
NCT00970359 Reacquisition of Radioactive Iodine RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244 View
NCT05926960 A Study Comparing 3 Study Medicines Encorafenib Binimetinib Pembrolizumab to 2 Study Medicines Ipilimumab and Nivolumab in Patients With Advanced Melanoma View
NCT06640166 Encorafenib Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib Cetuximab View
NCT05988697 Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib View
NCT05985109 KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer View
NCT05985954 Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination with Cetuximab and Encorafenib in Patients with Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy View
NCT06008119 Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer View
NCT02392871 Radiotherapy Combi in Metastatic Melanoma View
NCT06079333 NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid NEO-ATACT Study View
NCT01107418 A PharmacokineticPharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma View
NCT01124669 Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate View
NCT01155453 A Study to Investigate Safety Pharmacokinetics PK and Pharmacodynamics PD of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients View
NCT01166126 TemsirolimusAZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV View
NCT06159478 Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer Perfume View
NCT06208124 A Study of IMM-6-415 in RASRAF Mutant Solid Tumors View
NCT01243372 Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer View
NCT06262919 Special Drug Use-results Surveillance of TafinlarMekinist View
NCT06264778 Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma View
NCT06279351 Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer View
NCT01320085 A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma View
NCT01337765 Safety Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients View
NCT06317246 Subtypes and Prognostic Factors in Erdheim-Chester Disease View
NCT06337617 A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar Dabrafenib Plus Mekinist Trametinib in Chinese Patients With BRAF V600 Mutation Positive Melanoma View
NCT02672358 Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC View
NCT01378975 A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases View
NCT06374602 Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer View
NCT01436656 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma View
NCT06443866 I-124 PETCT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer View
NCT06470880 Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy View
NCT02083484 Program for Pembrolizumab MK-3475 in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab MK-3475-030 View
NCT02083354 Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma View
NCT02097225 Onalespib Dabrafenib and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery View
NCT02109653 Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC View
NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations View
NCT01400451 Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 BRAF View
NCT02902029 Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma View
NCT02133222 Circulating Cell-free DNA in Metastatic Melanoma Patient Mutational Analyses in Consecutive Measurement Before and After Chemotherapy View
NCT05501912 A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors View
NCT01072175 Investigate Safety Pharmacokinetics and Pharmacodynamics of GSK2118436 GSK1120212 View
NCT03944772 Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy ORCHARD View
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands View
NCT05786924 A Study of BDTX-4933 in Patients With KRAS BRAF and Select RASMAPK Mutation-Positive Cancers View
NCT04720768 Encorafenib Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE View
NCT02162563 Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases View
NCT05503797 A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations View
NCT02827565 Technical Optimization of Detection of KRAS BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer View
NCT02171286 The Oncopanel Pilot TOP Study View
NCT02175654 Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer mCRC With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab View
NCT00880321 A Phase I Study to Investigate the Safety Pharmacokinetics and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors View
NCT02196181 Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery View
NCT02202200 Phase I-II Study With Tumor Molecular Pharmacodynamic MPD Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma View
NCT02382549 A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib View
NCT05270044 Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation View
NCT01138085 Safety Pharmacokinetics PK of AKT and MEK Combination View
NCT02354690 Vemurafenib and TIL Therapy for Metastatic Melanoma View
NCT01271803 A Study of Vemurafenib and GDC-0973 Cobimetinib in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma View
NCT01336634 Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic Stage IV Non-small Cell Lung Cancer View
NCT01340846 A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin the Effects of Ketoconazole and Gemfibrozil on GSK2118436 and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors View
NCT01491633 Dasatinib in Advanced Squamous Cell Lung Cancer View
NCT01543698 A Phase IbII Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors View
NCT01551693 STA-9090Ganetespib in Patients With Unresectable Stage III or Stage IV Melanoma View
NCT02818023 Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma View
NCT04034459 FOLFOXIRI Plus Cetuximab vs FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC View
NCT04059224 TraMel-WT A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma View
NCT05510466 Triple BRAFinhMEKinh antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis View
NCT04201457 A Trial of Dabrafenib Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration View
NCT05510895 Neoadjuvant Encorafenib Binimetinib and Cetuximab for Patients With BRAF V600E MutatedpMMR Localized Colorectal Cancer View
NCT05370469 Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies View
NCT05511688 National Cohort of Colorectal Cancers With Microsatellite Instability View
NCT05538130 A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors View
NCT02279004 A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care View
NCT02278133 Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer mCRC and Wnt Pathway Mutations View
NCT02296996 Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients View
NCT02313012 Safety and PK Study of CC-90003 in RelapsedRefractory Solid Tumors View
NCT02316496 Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study View
NCT02323724 APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS View
NCT00338377 Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Immunization in Patients with Metastatic Melanoma View
NCT02399943 A Trial of Trametinib and Panitumumab in RASRAF Wild Type Advanced Colorectal Cancer View
NCT02736305 Use of Regorafenib in Recurrent Epithelial Ovarian Cancer View
NCT02768207 A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 BRAF V600 Mutation on Cell-Free Deoxyribonucleic Acid cfDNA From Plasma in Participants With Advanced Melanoma View
NCT02788669 LRP1 and Colon Cancer View
NCT02840409 Vinblastine - Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma LGG View
NCT02858921 Neoadjuvant Dabrafenib Trametinib andor Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma View
NCT02862743 Molecular Characterization of Advanced Stage Melanoma by Blood Sampling View
NCT02974803 Concurrent Dabrafenib Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases View
NCT03026517 Clinical Trial of Phenformin in Combination With BRAF Inhibitor MEK Inhibitor for Patients With BRAF-mutated Melanoma View
NCT03013491 PROCLAIM-CX-072 A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas View
NCT03015675 IV Ascorbic Acid in Advanced Gastric Cancer View
NCT03042221 Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR ALK ROS1 or BRAF TKI Therapy View
NCT03178851 Cobimetinib Targeted Therapy Plus Atezolizumab Immunotherapy in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma View
NCT03363347 BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer View
NCT03410875 A Phase II Study of the BRAF Inhibitor Vemurafenib Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia View
NCT03482362 Vinorelbine in Advanced BRAF-like Colon Cancer View
NCT03576937 Achieving Value in Cancer Diagnostics Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study View
NCT03600701 Atezolizumab and Cobimetinib in Treating Patients With Metastatic Recurrent or Refractory Non-small Cell Lung Cancer View
NCT03732703 Myeloma-Developing Regimens Using Genomics MyDRUG View
NCT03754179 DabrafenibTrametinibHydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma View
NCT03778138 Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC View
NCT03790228 Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC View
NCT03864042 Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors View
NCT03915951 An Open-label Study of Encorafenib Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer View
NCT03914170 Folfirinox Cetuximab Chemotherapy in First Line With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer View
NCT03926260 Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA View
NCT03951389 INST 1204 PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer View
NCT04034667 Study of CT and MR in the Lung Cancer View
NCT04080843 Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients View
NCT04151342 CAnadian CAncers With Rare Molecular Alterations CARMA - Basket Real-world Observational Study BROS View